Sökning: WFRF:(Friman G) >
12-month follow-up ...
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus
-
Levy, G. (författare)
-
Grazi, G. L. (författare)
-
Sanjuan, F. (författare)
-
visa fler...
-
Wu, Y. (författare)
-
Muhlbacher, F. (författare)
-
Samuel, D. (författare)
-
- Friman, Styrbjörn, 1948 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
Jones, R. (författare)
-
Cantisani, G. (författare)
-
Villamil, F. (författare)
-
Cillo, U. (författare)
-
Clavien, P. A. (författare)
-
Klintmalm, G. (författare)
-
Otto, G. (författare)
-
Pollard, S. (författare)
-
McCormick, P. A. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2006
- 2006
- Engelska.
-
Ingår i: Liver transplantation. - 1527-6465. ; 12:10, s. 1464-72
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- The LIS2T study was an open-label, multicenter study in which recipients of a primary liver transplant were randomized to cyclosporine microemulsion (CsA-ME) (Neoral) (n = 250) (monitoring of blood concentration at 2 hours postdose) C2 or tacrolimus (n = 245) (monitoring of trough drug blood level [predose]) C0 to compare efficacy and safety at 3 and 6 months and to evaluate patient status at 12 months. All patients received steroids with or without azathioprine. At 12 months, 85% of CsA-ME patients and 86% of tacrolimus patients survived with a functioning graft (P not significant). Efficacy was similar in deceased- and living-donor recipients. Significantly fewer hepatitis C-positive patients died or lost their graft by 12 months with CsA-ME (5/88, 6%) than with tacrolimus (14/85, 16%) (P < 0.03). Recurrence of hepatitis C virus in liver grafts was similar in each group. Based on biopsies driven by clinical events, the mean time to histological diagnosis of hepatitis C virus recurrence was significantly longer with CsA-ME (100 +/- 50 days) than with tacrolimus (70 +/- 40 days) (P < 0.05). Median serum creatinine at 12 months was 106 mumol/L with CsA-ME and with tacrolimus. More patients who were nondiabetic at baseline received antihyperglycemic therapy in the tacrolimus group at 12 months (13% vs. 5%, P < 0.01). Of patients who were diabetic at baseline, more tacrolimus-treated individuals required anti-diabetic treatment at 12 months (70% vs. 49%, P = 0.02). Treatment for de novo or preexisting hypertension or hyperlipidemia was similar in both groups. In conclusion, the efficacy of CsA-ME monitored by blood concentration at 2 hours postdose and tacrolimus in liver transplant patients is equivalent to 12 months, and renal function is similar. More patients required antidiabetic therapy with tacrolimus regardless of diabetic status at baseline.
Nyckelord
- Age Distribution
- Creatinine/blood
- Cyclosporine/administration & dosage/adverse effects/blood/*therapeutic
- use
- Diabetes Mellitus/drug therapy/epidemiology
- Emulsions/administration & dosage/adverse effects/therapeutic use
- Female
- Follow-Up Studies
- Graft Rejection/epidemiology
- Graft Survival
- Hepacivirus/*isolation & purification
- Humans
- Hypoglycemic Agents/therapeutic use
- Immunosuppressive Agents/administration & dosage/adverse
- effects/blood/*therapeutic use
- *Liver Transplantation
- Living Donors
- Longitudinal Studies
- Male
- *Monitoring
- Physiologic
- Steroids/therapeutic use
- Survival Analysis
- Tacrolimus/administration & dosage/adverse effects/blood/*therapeutic use
- Time Factors
- Treatment Outcome
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Levy, G.
-
Grazi, G. L.
-
Sanjuan, F.
-
Wu, Y.
-
Muhlbacher, F.
-
Samuel, D.
-
visa fler...
-
Friman, Styrbjör ...
-
Jones, R.
-
Cantisani, G.
-
Villamil, F.
-
Cillo, U.
-
Clavien, P. A.
-
Klintmalm, G.
-
Otto, G.
-
Pollard, S.
-
McCormick, P. A.
-
visa färre...
- Artiklar i publikationen
-
Liver transplant ...
- Av lärosätet
-
Göteborgs universitet